LAS VEGAS—A novel multivitamin antioxidant nutraceutical may be useful in the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis (HD) patients, according to data reported at the National Kidney Foundation’s Spring Clinical Meetings.
LAS VEGAS—Statin use by non-diabetic patients with end-stage renal disease may decrease paricalcitol use, researcher reported at the National Kidney Foundation’s Spring Clinical Meetings.
LAS VEGAS—Inpatient cost savings may offset the costs of patient adherence to cinacalcet therapy, according to study findings presented at the National Kidney Foundation’s Spring Clinical Meetings.
LAS VEGAS—Replacing 25-hydroxyvitamin D (25(OH)D) in hemodialysis (HD) patients who are deficient in the vitamin does not result in a significant decrease in intact parathyroid hormone (iPTH) level, researchers reported at the National Kidney Foundation’s Spring Clinical Meetings.
LAS VEGAS—Disordered mineral metabolism starts earlier in the course of chronic kidney disease (CKD) and is more severe in patients with diabetes than in those without diabetes, investigators reported at the National Kidney Foundation’s Spring Clinical Meetings.
LAS VEGAS—Cinacalcet is effective for the long-term management of persistent hyperparathyroidism after renal transplantation, with deleterious impact on kidney function, researchers reported at the National Kidney Foundation’s Spring Clinical Meeting.
Please login or register first to view this content.
